Overview

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Adenocorticotrophic Hormone provides safe and effective treatment to induce disease remission in rheumatoid arthritis patients with active disease due to an inadequate response to methotrexate.
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborator:
Mallinckrodt
Treatments:
Adrenocorticotropic Hormone
Methotrexate